Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer

American Journal of Pathology

Volumn 177, Issue 2, 2010, Pages 918-929

  Rödel, Franz ^a   Keppner, Sarah ^a   Capalbo, Gianni ^a   Bashary, Robina ^a   Kaufmann, Manfred ^a   Rödel, Claus ^a   Strebhardt, Klaus ^a   Spänkuch, Birgit ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; POLO LIKE KINASE 1; SMALL INTERFERING RNA;

ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CLONOGENIC ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; REAL TIME POLYMERASE CHAIN REACTION; RECTUM BIOPSY; RECTUM CANCER; RECURRENCE RISK; TUMOR BIOPSY; TUMOR REGRESSION; WESTERN BLOTTING;

EID: 77957259264     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100040     Document Type: Article

References (45)

1. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696 (Pubitemid 46211512)
2. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ: Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 2006, 32:55-64 (Pubitemid 43103989)
3. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Fuzesi L, Langer C, Becker H, Liersch T, Ried T: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005, 23:1826-1838 (Pubitemid 46217459)
4. Eckerdt F, Yuan J, Strebhardt K: Polo-like kinases and oncogenesis. Oncogene 2005, 24:267-276
5. Strebhardt K, Ullrich A: Targeting Polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006, 6:321-330
6. Glover DM, Hagan IM, Tavares AA: Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998, 12:3777-3787
7. Barr FA, Sillje HH, Nigg EA: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004, 5:429-440
8. Archambault V, Glover DM: Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009, 10:265-275
9. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M: Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002, 359:131-132 (Pubitemid 34112543)
10. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K: Prognostic significance of Polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:2794-2797 (Pubitemid 29283110)
11. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S: Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003, 94:148-152 (Pubitemid 36575873)
12. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Muller BM, Niesporek S, Dietel M, Denkert C: Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005, 446:442-450 (Pubitemid 40674853)
13. Lane HA, Nigg EA: Antibody microinjection reveals an essential role for human Polo-like kinase 1 (PLK1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996, 135:1701-1713
14. Liu X, Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003, 100:5789-5794 (Pubitemid 36576886)
15. Cogswell JP, Brown CE, Bisi JE, Neill SD: Dominant-negative Polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000, 11:615-623
16. Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, von Minckwitz G, Kaufmann M, Strebhardt K: Downregulation of human Polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002, 21:3162-3171 (Pubitemid 34548087)
17. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K: Effect of RNA silencing of Polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002, 94:1863-1877
18. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K: Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004, 96:862-872
19. Keppner S, Proschak E, Schneider G, Spankuch B: Identification and validation of a potent type II inhibitor of inactive Polo-like kinase 1. ChemMedChem 2009, 4:1806-1809
20. Lenart P, Petronczki M, Steegmaier M, Di FB, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM: The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of Polo-like kinase 1. Curr Biol 2007, 17:304-315
21. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gurtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ: BI 2536, a potent and selective inhibitor of Polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007, 17:316-322
22. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP: ON01910, a non-ATP-competitive small molecule inhibitor of PLK1, is a potent anticancer agent. Cancer Cell 2005, 7:275-286
23. McInnes C, Mezna M, Fischer PM: Progress in the discovery of Polo-like kinase inhibitors. Curr Top Med Chem 2005, 5:181-197
24. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG: Distinct concentration-dependent effects of the Polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009, 69:6969-6977
25. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH: Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000, 2:672-676
26. van Vugt MA, Smits VA, Klompmaker R, Medema RH: Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR- dependent fashion. J Biol Chem 2001, 276:41656-41660
27. Ree AH, Bratland A, Solberg LK, Fodstad O: Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner. Anticancer Res 2004, 24:555-562
28. Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, Medema RH: Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455:119-123
29. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003, 21:3098-3104
30. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Furst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sulberg H, Hohenberger W, Sauer R: Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007, 25:110-117
31. Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K: Rational combinations of siRNAs targeting PLK1 with breast cancer drugs. Oncogene 2007, 26:5793-5807
32. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Jr., Kinzler KW, Vogelstein B, Papadopoulos N: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009, 106:3964-3969
33. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K: Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006, 66:5836-5846
34. Spankuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko E, Strebhardt KI, Langer K: Downregulation of PLK1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 2008, 10:223-234
35. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65:4881-4887
36. Schlingemann J, Habtemichael N, Ittrich C, Toedt G, Kramer H, Hambek M, Knecht R, Lichter P, Stauber R, Hahn M: Patient-based cross-platform comparison of oligonucleotide microarray expression profiles. Lab Invest 2005, 85:1024-1039
37. Knecht R, Oberhauser C, Strebhardt K: PLK (Polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000, 89:535-536
38. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997, 12:19-23
39. Shirayama M, Zachariae W, Ciosk R, Nasmyth K: The Polo-like kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiae. EMBO J 1998, 17:1336-1349
40. Descombes P, Nigg EA: The Polo-like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts. EMBO J 1998, 17:1328-1335
41. Nigg EA: Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 1998, 10:776-783
42. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O: Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene 2003, 22:8952-8955
43. van Vugt MA, van de Weerdt BC, Vader G, Janssen H, Calafat J, Klompmaker R, Wolthuis RM, Medema RH: Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004, 279:36841-36854
44. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J, Bartek J: Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005, 25:3553-3562
45. Keppner S, Proschak E, Kaufmann M, Schneider G, Strebhardt K, Spankuch B: Biological impact of freezing PLK1 in its inactive conformation on cancer cells. Cell Cycle 2009, 9:761-774